Breast cancer after Hodgkin disease: hope for a safer cure.
J. Yahalom
DOI: https://doi.org/10.1001/JAMA.290.4.529
2003-07-23
Abstract:FOR MORE THAN A CENTURY, HODGKIN DISEASE (HD) has served as a paradigm for developing modern oncology concepts. Yet the success of using radiotherapy, chemotherapy, or both for cure of a formerly lethal disease has not come without a price. Even though control of HD in early-stage and overall survival is approximately 90% at 10 years, survival is decreasing with more years of observation, primarily due to a higher than expected number of deaths from second malignancies. At 20 years after diagnosis, the cumulative risk of developing second cancers is approximately 10%, exceeding the cumulative risk of dying from the primary early-stage disease. For women whose HD was successfully treated at a young age, the main long-term concern is the increased risk of breast cancer. During the last decade, multiple studies have documented and characterized the risk of breast cancer after HD, and have established 3 facts. First, the increased risk of breast cancer is undoubtedly associated with the use of radiation. Radiotherapy alone had been the standard treatment and primary curative modality for HD through the 1970s and early 1980s. Irradiating all lymph node regions, regardless of clinical involvement with HD, has been standard practice, and relatively high doses ( 40 Gy) have been used. Consequently, a substantial amount of breast tissue has been exposed to either the full prescribed dose or to an attenuated dose (at field margins or under the lung shields) in almost all women receiving radiotherapy for HD. Second, the increased risk of breast cancer is agerelated, with the highest risk associated with treatment at ages 10 years to 20 years. The risk remains significantly increased until age 25 years or 30 years, and disappears thereafter. Third, the increased risk is manifested late, the median time from HD treatment to breast cancer is 15 years, and only few events have been reported at the first decade after HD. This explains why the increase in risk of breast cancer became statistically apparent only about 10 years ago. However, several critical issues regarding the increased risk of breast cancer have remained unknown or controversial, including the magnitude of the risk as related only to treatment, the impact of radiation dose and exposed breast volume on the risk, and the effect of chemotherapy in either enhancing or decreasing the risk. These issues are of biological interest, have direct relevance to evaluating the risk of current practice, may influence the design of new strategies for treatment of HD, and possibly may support interventions to reduce risk of breast cancer in women previously treated with radiation that resulted in breast exposure. In this issue of THE JOURNAL, Travis and colleagues from 13 centers in 7 countries provide important data that help decipher most of these issues. Their case-control study included 105 women who developed breast cancer within a cohort of more than 38001-year female survivors of HD diagnosed at age 30 years or younger. Unique to this study is the inclusion of patients who received a very low dose of radiation ( 4 Gy) or no radiation to the breast area where breast cancer developed. This approach allowed the isolation of treatment factors as well as the analysis of the relationships between risks associated with radiation and chemotherapy doses. For all patients who received radiotherapy alone ( 4 Gy) the relative risk (RR) of breast cancer was 3.2 and increased to 8.0 in the group receiving the highest dose of radiation. Although this risk is significant, it is at the lower end of the previously reported range of RRs (ie, large studies have reported RRs ranging from 2 to 450). In the largest long-term follow-up study of second neoplasms in survivors of HD, which included data from 16 cancer registries of more than 35000 patients, the RR for breast cancer in women was 2.0 and the absolute excess risk was 10.5. Unfortunately, RRs, absolute risks, and actuarial risks are often cited without detailing specifics that could have influenced the findings (ie, length of follow-up for the group and for the individuals; age group, ageincidence, and actuarial risk of the malignancy in an untreated population; and quality of follow-up, which may result in event overestimation). In the study by Travis et al, the reference point (RR=1.0) consists of patients with breast cancer diagnosed after treatment of HD using low-dose or no radiation, thus allowing